539. GS-CA2: A Novel, Potent, and Selective First-In-class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in Humans
Jim Zheng(Gilead Sciences (United States)), Winston C. Tse(Gilead Sciences (United States)), Shekeba Ahmadyar(Gilead Sciences (United States)), Raju Subramanian(Gilead Sciences (United States)), Tomáš Cihlář(Gilead Sciences (United States)), Kelly Wei Wang(Gilead Sciences (United States)), William Rowe(Gilead Sciences (United States)), Stephen R. Yant(Gilead Sciences (United States)), John O. Link(Gilead Sciences (United States)), Tiffany Y Chan(Gilead Sciences (United States)), Bing Lu(Gilead Sciences (United States)), Scott D. Schroeder(Gilead Sciences (United States)), Judy Mwangi(Gilead Sciences (United States)), Anna Chiu(Gilead Sciences (United States)), George Stepan(Gilead Sciences (United States))
Cited by 15
Related Papers
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
|Cell Reports|2020|541
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
|Drug Metabolism and Disposition|2002|346
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
|Drug Metabolism and Disposition|2002|325